MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
*Driving Forces: Market Research, Intelligence, Analysis, Datapoints, Databases & Trends
2023: Top 20 Genomics Companies in the World
CRISPR Therapeutics AG (NASDAQ:CRSP)*
Organization & Developments: CRISPR Therapeutics
Parents
CRISPR Therapeutics AG (NASDAQ:CRSP)*
Children
2016: The $105 million deal included $75 million in cash and a $30 million equity investment to develop treatments for cystic fibrosis and sickle cell disease. Vertex has exclusive rights under the deal to license up to six new Crispr-Cas9 treatments from
2018: CRISPR Therapeutics and Vertex Announce FDA Has Lifted the Clinical Hold on the Investigational New Drug Application for CTX001 for the Treatment of Sickle Cell Disease Nasdaq:CRSP
2018: CRISPR Therapeutics: Buy The Secondary - CRISPR Therapeutics (NASDAQ:CRSP)
2019: Better Buy: Editas Medicine vs. CRISPR Therapeutics
2019: CRISPR Therapeutics and Vertex Announce FDA Fast Track…
2020: CRISPR Therapeutics: A Review Of Its Clinical Pipeline And Progress _seekingalpha.com
2020: Crispr Therapeutics: My #1 High-Risk Investment Idea
2020: Crispr: The Frontier Of Gene Editing
2021: CRISPR Therapeutics: Roadblock Ahead
2021: CRISPR Therapeutics: Still A Solid Bet - Sickle Cell Disease Approval Possible Within 3 Years
2021: Crispr Therapeutics: Strong Partnership And Data Development
2022: CRISPR heads to the FDA_Vertex and CRISPR Therapeutics Announce Global exa-cel Regulatory Submissions for Sickle Cell Disease and Beta Thalassemia in 2022_vrtx
2022: CRISPR Therapeutics - Progress Adds More Value Than Patent Setback Subtracts_seekingalpha.com
2022: CRISPR Therapeutics AG 2022 Q4 - Results - Earnings Call Presentation_seekingalpha.com
2022: Crispr Therapeutics: Nearing Harvest Season_seekingalpha.com
2022: Crispr Therapeutics: The Pick Of The Gene Therapy Bunch_ seekingalpha.com
2022: Crispr: Elucidating And Forecasting Key Developments_ seekingalpha.com
2023: Bull of the Day: CRISPR Therapeutics (CRSP)
2023: CRISPR Therapeutics AG (NASDAQ:CRSP)_seekingalpha.com
2023: CRISPR Therapeutics laid off employees on heels of positive FDA AdComm: sources_
2023: CRISPR Therapeutics: 2023 Could Be The Right Year_seekingalpha.com
2023: Crispr Therapeutics: ICER Puzzles The Prospects
2023: CRISPR Therapeutics: Positive Exa-Cel AdCom Opens Door For Historic Approval (CRSP)
2023: CRISPR Therapeutics: Therapies Of The Future Are Almost Here, But Not Yet_seekingalpha.com
2023: Crispr Therapeutics: Upside Likely Coming Now That Exa-Cel Is With FDA_ seekingalpha.com
2023: Crispr: Upcoming Catalysts, Plenty Of Cash And Strong Partnerships Make It A Buy_seekingalpha
2023: FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease
2023: Hold Until A Firmer Decision Date (NASDAQ:CRSP)
2023: Risk And Reward: Evaluating Crispr's Exa-Cel For Sickle Cell
2023: Vertex and CRISPR Therapeutics Announce Authorization of the First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), by the United Kingdom MHRA for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
2023: Vertex And CRISPR Therapeutics: Historic Exa-cel Approval, Why Market Is Nonplussed_ seekingalpha.com
2024: CRISPR Therapeutics
2024: CRISPR Therapeutics (NASDAQ:CRSP) Boasts Solid Potential and Limited Risk_www.tipranks.com
2024: Crispr Therapeutics Is Overvalued (Rating Downgrade)_ seekingalpha.com
2024: Crispr Therapeutics Q2 Earnings: Casgevy Updates Underline 'Blockbuster' Potential
2024: Crispr Therapeutics Q3 Earnings: No Casgevy Revenue, But Plenty Of Optimism_seekingalpha.com
2024: Crispr Therapeutics: Avoid Catching The Falling Knife This Time (Downgrade)
2024: Crispr Therapeutics: Cautiously Optimistic
2024: Crispr Therapeutics: From Casgevy Success To A Catalyst-Rich 2025_ seekingalpha.com
2024: Crispr Therapeutics: I'm Not Betting Against Gene Editing This Time (Upgrade)_ seekingalpha.com
2024: Crispr Therapeutics: Poised For A Major Turnaround
2024: CRISPR Therapeutics: Strong Balance Sheet Supports Ambitious Plans Amid Slow Growth
2024: Crispr Therapeutics: Upcoming Catalysts May Validate The Bull Thesis And Force A Change In Plans
2024: Crispr's Casgevy Launch: Promising Start, Uncertain Future
2024: Cutting Edge Gene Therapy_ Vertex Pharmaceuticals and CRISPR Therapeutics Casgevy
2024: In Another Win for CRISPR, FDA Approves Casgevy for Beta Thalassemia
2024: Patients At Last Begin Receiving Vertex-CRISPR and Bluebird Sickle Cell Gene Therapies
2024: Vertex And Crispr: Second Casgevy Approval Pushes Revenue Potential Into Multi-Billion Dollar Range_seekingalpha.com
2025: A Gene-Editing Therapy Cut Cholesterol Levels by Half
2025: Crispr Therapeutics Q1 Earnings Analysis: Ignore The Gloom, Stay The Course
2025: Crispr Therapeutics Q4 Earnings Review: Ignore The Lack Of Revenues, Buy The Future
2025: CRISPR Therapeutics sees 80% fall in LDL, triglycerides after in vivo liver editing
2025: CRISPR Therapeutics Struggles Under Slow Adoption And Regulatory Uncertainty (Downgrade)
2025: Crispr Therapeutics: A Winning Lottery Ticket Doesn't Replace Grand Strateg
2025: CRISPR Therapeutics: An Uninspiring Start For Casgevy
2025: Crispr Therapeutics: Betting On A One-Shot Future
2025: Crispr Therapeutics: Complex Casgevy Launch, But Broader Gene-Editing Potential Still Shines
2025: Crispr Therapeutics: Early-Stage Research Updates Show Promise
2025: CRISPR Therapeutics: Unfairly Punished By The Issues Of Its Peers
2025: Crispr Therapeutics: Why I've Become Even More Bullish (Rating Upgrade)
2026: 44th Annual J.P. Morgan Healthcare Conference (NASDAQ:CRSP) 2026-01-12
Jumps
*Key People: CRISPR Therapeutics
Finance & Acquisitions: CRISPR Therapeutics